Advertisement

A Retrospective Study of Treatment Outcomes in Patients With Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile

Published:October 17, 2011DOI:https://doi.org/10.1016/j.clcc.2011.08.001

      Abstract

      Background

      Molecular tumor profiling is a new method of identifying the tissue of origin in patients with carcinoma of unknown primary (CUP) site. However the value of this information in improving treatment outcomes is undefined. We evaluated results of site-specific treatment in a group of patients with CUP in whom molecular profiling predicted a colorectal site of origin.

      Patients and Methods

      Tissue of origin predictions by a 92-gene real-time polymerase chain reaction (RT-PCR) molecular profiling assay (CancerTYPE ID; bioTheranostics, Inc, San Diego, CA) from March 2008 to August 2009 were reviewed. One hundred twenty-five of 1544 patients (8%) assayed were predicted to have a colorectal tissue of origin with > 80% probability. Surveys were sent to the physicians of these 125 patients requesting deidentified patient information.

      Results

      Information was provided for 42 of 125 patients (34%). Thirty-two patients received either first- or second-line therapy with colorectal cancer regimens; the overall response rate was 50%. Patients who received first-line empirical therapy for CUP had an overall response rate of 17%. The median survival of patients who received site-specific therapy for colorectal cancer was 27 months.

      Conclusions

      Patients predicted to have a colorectal site of origin by molecular tumor profiling had median survival when treated with site-specific regimens that was similar to survival in patients with known metastatic colon cancer. The median survival in this group was substantially better than the historical median survival for patients with CUP (range 8-11 months) when treated with empirical CUP regimens. Molecular tumor profiling seems to improve survival by allowing specific therapy in this patient subgroup; prospective trials are ongoing to confirm these observations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Culine S.
        • Lortholary A.
        • Voigt J.J.
        • et al.
        Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
        J Clin Oncol. 2003; 21: 3479-3482
        • Greco F.A.
        • Pavlidis N.
        Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors.
        Semin Oncol. 2009; 36: 65-74
        • Huebner G.
        • Link H.
        • Kohne C.H.
        • et al.
        Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
        Br J Cancer. 2009; 100: 44-49
        • Grothey A.
        • Sugrue M.M.
        • Purdie D.M.
        • et al.
        Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
        J Clin Oncol. 2008; 26: 5326-5334
        • Saltz L.B.
        • Clarke S.
        • Diaz-Rubio E.
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Pentheroudakis G.
        • Golfinopoulos V.
        • Pavlidis N.
        Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
        Eur J Cancer. 2007; 43: 2026-2036
        • Bloom G.
        • Yang I.V.
        • Boulware D.
        • et al.
        Multi-platform, multi-site, microarray-based human tumor classification.
        Am J Pathol. 2004; 164: 9-16
        • Su A.I.
        • Welsh J.B.
        • Sapinoso L.M.
        • et al.
        Molecular classification of human carcinomas by use of gene expression signatures.
        Cancer Res. 2001; 61: 7388-7393
        • Ma X.J.
        • Patel R.
        • Wang X.
        • et al.
        Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay.
        Arch Pathol Lab Med. 2006; 130: 465-473
        • Monzon F.A.
        • Medeiros F.
        • Lyons-Weiler M.
        • et al.
        Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
        Diagn Pathol. 2010; 5: 3
        • Kaplan E.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Greco F.A.
        • Spigel D.R.
        • Yardley D.A.
        • et al.
        Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.
        Oncologist. 2010; 15: 500-506
        • Horlings H.M.
        • van Laar R.K.
        • Kerst J.M.
        • et al.
        Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
        J Clin Oncol. 2008; 26: 4435-4441
        • Varadhachary G.R.
        • Edmonston T.B.
        • Karanth S.
        • et al.
        Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP).
        J Clin Oncol. 2010; 28 (abstract 4151) (Accessed: August 29, 2011)
        • Varadhachary G.R.
        • Talantov D.
        • Raber M.N.
        • et al.
        Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
        J Clin Oncol. 2008; 26: 4442-4448
        • Varadhachary G.R.
        • Raber M.N.
        • Matamoros A.
        • et al.
        Carcinoma of unknown primary with a colon-cancer profile—changing paradigm and emerging definitions.
        Lancet Oncol. 2008; 9: 596-599
        • Bridgewater J.
        • van Laar R.
        • Floore A.
        • et al.
        Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary.
        Br J Cancer. 2008; 98: 1425-1430
        • Laar R.K.v.
        • Ma X.-J.
        • Jong D.D.
        • et al.
        Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.
        Int J Cancer. 2009; 125: 1390-1397
        • Talantov D.
        • Baden J.
        • Jatkoe T.
        • et al.
        A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin.
        J Mol Diagn. 2006; 8: 320-329
        • Tothill R.W.
        • Kowalczyk A.
        • Rischin D.
        • et al.
        An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
        Cancer Res. 2005; 65: 4031-4040
        • Hainsworth J.D.
        • Spigel D.R.
        • Rubin M.S.
        • et al.
        Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: a prospective, phase II trial.
        J Clin Oncol (Meeting Abstracts). 2010; 28 (abstract 10540)